[HTML][HTML] Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study
Background Men with high serum prostate specific antigen usually undergo transrectal
ultrasound-guided prostate biopsy (TRUS-biopsy). TRUS-biopsy can cause side-effects including …
ultrasound-guided prostate biopsy (TRUS-biopsy). TRUS-biopsy can cause side-effects including …
New guidelines to evaluate the response to treatment in solid tumors
…, EA Eisenhauer, J Wanders, RS Kaplan… - Journal of the …, 2000 - academic.oup.com
Anticancer cytotoxic agents go through a process by which their antitumor activity—on the
basis of the amount of tumor shrinkage they could generate—has been investigated. In the …
basis of the amount of tumor shrinkage they could generate—has been investigated. In the …
[HTML][HTML] Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 …
…, MJ Kennedy, B Claes, D Lambrechts, R Kaplan… - The Lancet, 2011 - thelancet.com
Background In the Medical Research Council (MRC) COIN trial, the epidermal growth factor
receptor (EGFR)-targeted antibody cetuximab was added to standard chemotherapy in first-…
receptor (EGFR)-targeted antibody cetuximab was added to standard chemotherapy in first-…
Cancer surveillance series: interpreting trends in prostate cancer—part I: evidence of the effects of screening in recent prostate cancer incidence, mortality, and …
…, LA Ries, RM Merrill, RS Kaplan - Journal of the …, 1999 - academic.oup.com
BACKGROUND: The prostate-specific antigen test was approved by the US Food and Drug
Administration in 1986 to monitor the disease status in patients with prostate cancer and, in …
Administration in 1986 to monitor the disease status in patients with prostate cancer and, in …
[PDF][PDF] Participation of patients 65 years of age or older in cancer clinical trials
…, DP Goldman, EL Trimble, R Kaplan… - Journal of clinical …, 2003 - researchgate.net
Purpose: Although 61% of new cases of cancer occur among the elderly, recent studies
indicate that the elderly comprise only 25% of participants in cancer clinical trials. Further …
indicate that the elderly comprise only 25% of participants in cancer clinical trials. Further …
Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working …
PURPOSE: Prostate-specific antigen (PSA) is a glycoprotein that is found almost exclusively
in normal and neoplastic prostate cells. For patients with metastatic disease, changes in …
in normal and neoplastic prostate cells. For patients with metastatic disease, changes in …
[HTML][HTML] Chronic neurologic manifestations of Lyme disease
EL Logigian, RF Kaplan, AC Steere - New England Journal of …, 1990 - Mass Medical Soc
Background and Methods. Lyme disease, caused by the tick-borne spirochete Borrelia
burgdorferi, is associated with a wide variety of neurologic manifestations. To define further the …
burgdorferi, is associated with a wide variety of neurologic manifestations. To define further the …
[HTML][HTML] Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 …
…, D Stark, AM Swart, L Farrelly, R Kaplan… - The Lancet …, 2015 - thelancet.com
Background The ICON7 trial previously reported improved progression-free survival in women
with ovarian cancer with the addition of bevacizumab to standard chemotherapy, with the …
with ovarian cancer with the addition of bevacizumab to standard chemotherapy, with the …
A clinical grading scale to predict malignant hyperthermia susceptibility.
…, MA Denborough, FR Ellis, GA Gronert, RF Kaplan… - …, 1994 - europepmc.org
Background The diagnosis of an acute malignant hyperthermia reaction by clinical criteria
can be difficult because of the nonspecific nature and variable incidence of many of the …
can be difficult because of the nonspecific nature and variable incidence of many of the …
Mismatch Repair Status and BRAF Mutation Status in Metastatic Colorectal Cancer Patients: A Pooled Analysis of the CAIRO, CAIRO2, COIN, and FOCUS Studies
Purpose: To determine the prevalence and prognostic value of mismatch repair (MMR)
status and its relation to BRAF mutation (BRAF MT ) status in metastatic colorectal cancer (mCRC)…
status and its relation to BRAF mutation (BRAF MT ) status in metastatic colorectal cancer (mCRC)…